Rotigotine
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Restless Legs Syndrome
Conditions
Idiopathic Restless Legs Syndrome
Trial Timeline
Jan 1, 2006 → Sep 1, 2007
NCT ID
NCT00498108About Rotigotine
Rotigotine is a phase 3 stage product being developed by UCB for Idiopathic Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00498108. Target conditions include Idiopathic Restless Legs Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03103919 | Approved | Completed |
| NCT01976871 | Approved | Completed |
| NCT01782222 | Approved | Completed |
| NCT01723904 | Phase 3 | Completed |
| NCT01711866 | Approved | Completed |
| NCT01569464 | Phase 3 | Completed |
| NCT01498120 | Phase 2 | Completed |
| NCT01495793 | Phase 2 | Completed |
| NCT01300819 | Approved | Completed |
| NCT00594464 | Approved | Completed |
| NCT00593606 | Phase 3 | Completed |
| NCT00519532 | Phase 3 | Terminated |
| NCT00474058 | Phase 3 | Completed |
| NCT01964573 | Phase 1 | Completed |
| NCT00498108 | Phase 3 | Completed |
| NCT00263068 | Phase 3 | Completed |
| NCT00275236 | Phase 3 | Completed |
| NCT00135993 | Phase 3 | Completed |
| NCT00136045 | Phase 3 | Completed |
| NCT00505687 | Phase 3 | Completed |
Competing Products
20 competing products in Idiopathic Restless Legs Syndrome